BCBradley A. Connor

Bradley A. Connor

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bradley A. Connor has a total of 76 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Is standby therapy for Covid-19 a practical option for travellers?

    by Lin H Chen, Bradley A Connor

    Covid-19 vaccines and therapeutics developed through remarkable efforts have helped bolster public confidence to reopen the world and to restart travel. 1 Covid-19 vaccines on the World Health Organization Emergency Use Listing [Covid-19 Vaccines with WHO Emergency Use Listing. Available at: https://extranet.who.int/pqweb/vaccines/vaccinescovid-19-vaccine-eul-issued] are generally—but not always—accepted by many countries and jurisdictions. Many countries have imposed vaccine requirements for travel, which have evolved over time. The emergence of SARS-CoV-2 variants and the ‘immune escape’ that they exhibit have introduced concern about potential decline of protection from Covid-19 vaccines. 2


  • Open Access

    Comparative Effectiveness of Single vs Repeated Rapid SARS-CoV-2 Antigen Testing Among Asymptomatic Individuals in a Workplace Setting

    by Bradley A. Connor, Marina Rogova, Jefferson Garcia, Darshan Patel, Mara Couto-Rodriguez, Dorottya Nagy-Szakal, Michael Rendel

    The gold standard for diagnostic testing for SARS-CoV-2 is real-time reverse transcriptase–polymerase chain reaction (RT-qPCR).1 Because of lag times in obtaining results and the expense of this diagnostic modality, rapid antigen testing has been frequently used for screening of asymptomatic populations instead.2 Several SARS-CoV-2 rapid antigen tests are available in the US with Emergency Use Authorization by the US Food and Drug Administration based on data from symptomatic patients.3 Although rapid antigen tests have been criticized for poor sensitivity and specificity when screening asymptomatic patients, a knowledge gap still remains regarding the utility of these tests for screening.4 Given the large cohort of individuals being screened by an international service company based in New York City, we sought to analyze the comparative effectiveness and estimated accuracy of an employee screening program using single vs repeated antigen tests compared with RT-qPCR among asymptomatic individuals.


  • Open Access

    Acute hepatitis A in international travellers: a GeoSentinel analysis, 2008–2020

    by Oluwafemi Balogun, Ashley Brown, Kristina M Angelo, Natasha S Hochberg, Elizabeth D Barnett, Laura Ambra Nicolini, Hilmir Asgeirsson, Martin P Grobusch, Karin Leder, Fernando Salvador, et al.

    Non-immune international travellers are at risk of acquiring hepatitis A. Although hepatitis A vaccination is recommended for unvaccinated travellers to high or intermediate hepatitis A virus endemicity, compliance with this recommendation is not universal. The main objective was to describe the demographic and travel characteristics of international travellers infected with hepatitis A during travel. Available data on travellers with confirmed (positive molecular test) or probable (symptomatic individuals with a single positive IgM test) hepatitis A diagnosed during and after travel from January 2008 to December 2020 were obtained from the GeoSentinel Surveillance Network database. We analysed demographic and travel characteristics of infected travellers. Among 254 travellers with hepatitis A (185 confirmed and 69 probable), the median age was 28 years (interquartile range: 19–40), 150 (59%) were male, and among 54 travellers with information available, 53 (98%) were unvaccinated. The most common reasons for travel included tourism (n = 120; 47%) and visiting friends or relatives (VFR; n = 72; 28%). About two-thirds of VFR travellers with hepatitis A (n = 50; 69%) were younger than 20 years old. Hepatitis A was acquired most frequently in South-Central Asia (n = 63; 25%) and sub-Saharan Africa (n = 61; 24%), but 16 travellers (6%) acquired hepatitis A in regions with low endemicity including Western Europe (n = 7; 3%), the Caribbean (n = 6; 2%) and North America (n = 3; 1%). Median duration from illness onset to GeoSentinel site presentation was ~7 days (interquartile range : 4–14 days). Among 88 travellers with information available, 59% were hospitalized. Despite availability of highly effective vaccines, travellers still acquire hepatitis A, even when traveling to low-endemicity destinations. Providing pre-departure hepatitis A vaccine to susceptible travellers is crucial to reducing travel-associated hepatitis A and should be offered to all travellers as part of the pre-travel consultation, regardless of destination.


  • Open Access

    Monoclonal Antibody Therapy in a Vaccine Breakthrough SARS-CoV-2 Hospitalized Delta (B.1.617.2) Variant Case

    by Bradley A Connor, Mara Couto-Rodriguez, Joseph E Barrows, Morgan Gardner, Marina Rogova, Niamh B. O'HAra, Dorottya Nagy-Szakal


  • What will travel medicine look like in the COVID-19 pandemic era?

    by David R Shlim, Bradley A Connor, David N Taylor

    Travel medicine has virtually stopped in light of the coronavirus pandemic. It is worth contemplating how travel medicine will be affected by the ongoing pandemic when international travel starts to become more possible. How will we advise patients and use the coming vaccines that may be available? Travel medicine practices are well-suited to play a major role in advising travellers in the pandemic era.


  • Open Access

    A dignitary medicine curriculum developed using a modified Delphi methodology

    by Mobarak A. Al Mulhim, Robert G. Darling, Ritu Sarin, Alex Hart, Hetaf Kamal, Abdullah Al Hadhirah, Amalia Voskanyan, Lewis Hofmann, Bradley A. Connor, Roger A. Band, et al.

    Background: Dignitary medicine is an emerging field of training that involves the specialized care of diplomats, heads of state, and other high-ranking officials. In an effort to provide guidance on training in this nascent field, we convened a panel of experts in dignitary medicine and using the Delphi methodology, created a consensus curriculum for training in dignitary medicine.Methods: A three-round Delphi consensus process was performed with 42 experts in the field of dignitary medicine. Predetermined scores were required for an aspect of the curriculum to advance to the next round. The scores on the final round were used to determine the components of the curriculum. Scores below the threshold to advance were dropped in the subsequent round.Results: Our panel had a high degree of agreement on the required skills needed to practice dignitary medicine, with active practice in a provider’s baseline specialty, current board certification, and skills in emergency care and resuscitation being the highest rated skills dignitary medicine physicians need. Skills related to vascular and emergency ultrasound and quality improvement were rated the lowest in the Delphi analysis. No skills were dropped from consideration.Conclusions: The results of our work can form the basis of formal fellowship training, continuing medical education, and publications in the field of dignitary medicine. It is clear that active medical practice and knowledge of resuscitation and emergency care are critical skills in this field, making emergency medicine physicians well suited to practicing dignitary medicine.


  • Open Access

    Cholera in travellers: a systematic review

    by Bradley A Connor, Richard Dawood, Mark S Riddle, Davidson H Hamer

    Exposure to cholera is a risk for individuals and groups travelling to endemic areas, and the bacteria can be imported to cholera-free countries by returning travellers. This systematic review of the literature describes the circumstances in which cholera infection can occur in travellers and considers the possible value of the cholera vaccine for prevention in travellers. PubMed and EMBASE were searched for case reports of cholera or diarrhoea among travellers, with date limits of 1 January 1990–30 April 2018. Search results were screened to exclude the following articles: diarrhoea not caused by cholera, cholera in animals, intentional cholera infection in humans, non-English articles and publications on epidemics that did not report clinical details of individual cases and publications of cases pre-dating 1990. Articles were reviewed through descriptive analytic methods and information summarized. We identified 156 cases of cholera imported as a consequence of travel, and these were reviewed for type of traveller, source country, serogroup of cholera, treatment and outcomes. The case reports retrieved in the search did not report consistent levels of detail, making it difficult to synthesize data across reports and draw firm conclusions from the data. This clinical review sheds light on the paucity of actionable published data regarding the risk of cholera in travellers and identifies a number of gaps that should drive additional effort. Further information is needed to better inform evidence-based disease prevention strategies, including vaccination for travellers visiting areas of cholera risk. Modifications to current vaccination recommendations to include or exclude current or additional traveller populations may be considered as additional risk data become available. The protocol for this systematic review is registered with PROSPERO (registration number: 122797).


  • Open Access

    Cutaneous and mucocutaneous leishmaniasis in travellers and migrants: a 20-year GeoSentinel Surveillance Network analysis

    by Andrea K Boggild, Eric Caumes, Martin P Grobusch, Eli Schwartz, Noreen A Hynes, Michael Libman, Bradley A Connor, Sumontra Chakrabarti, Philippe Parola, Jay S Keystone, et al.

    Cutaneous leishmaniasis (CL) may be emerging among international travellers and migrants. Limited data exist on mucocutaneous leishmaniasis (MCL) in travellers. We describe the epidemiology of travel-associated CL and MCL among international travellers and immigrants over a 20-year period through descriptive analysis of GeoSentinel data. Demographic and travel-related data on returned international travellers diagnosed with CL or MCL at a GeoSentinel Surveillance Network site between 1 September 1997 and 31 August 2017 were analysed. A total of 955 returned travellers or migrants were diagnosed with travel-acquired CL (n = 916) or MCL during the study period, of whom 10% (n = 97) were migrants. For the 858 non-migrant travellers, common source countries were Bolivia (n = 156, 18.2%) and Costa Rica (n = 97, 11.3%), while for migrants, they were Syria (n = 34, 35%) and Afghanistan (n = 22, 22.7%). A total of 99 travellers (10%) acquired their disease on trips of ≤ 2 weeks. Of 274 cases for which species identification was available, Leishmania Viannia braziliensis was the most well-represented strain (n = 117, 42.7%), followed by L. major (n = 40, 14.6%) and L. V. panamensis (n = 38, 13.9%). Forty cases of MCL occurred, most commonly in tourists (n = 29, 72.5%) and from Bolivia (n = 18, 45%). A total of 10% of MCL cases were acquired in the Old World. Among GeoSentinel reporting sites, CL is predominantly a disease of tourists travelling mostly to countries in Central and South America such as Bolivia where risk of acquiring L. V. braziliensis and subsequent MCL is high. The finding that some travellers acquired leishmaniasis on trips of short duration challenges the common notion that CL is a disease of prolonged travel. Migrants from areas of conflict and political instability, such as Afghanistan and Syria, were well represented, suggesting that as mass migration of refugees continues, CL will be increasingly encountered in intake countries.